One possible treatment for cancer involves monoclonal antibodies that bind only to cancer-cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin, radioisotope, cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab regions both to target antigen and to a conjugate or effector cell. Every intact antibody can bind to cell receptors or other proteins with its Fc region.
 MAbs approved by the FDA for cancer include:
* Alemtuzumab
* Bevacizumab
* Cetuximab
* Dostarlimab
* Gemtuzumab ozogamicin
* Ipilimumab
* Nivolumab
* Ofatumumab
* Panitumumab
* Pembrolizumab
* Ranibizumab
* Rituximab
* Trastuzumab